148 related articles for article (PubMed ID: 8851619)
1. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
Hoppe JE; Rahimi-Galougahi E; Seibert G
Antimicrob Agents Chemother; 1996 Mar; 40(3):807-8. PubMed ID: 8851619
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.
Hoppe JE; Simon CG
Antimicrob Agents Chemother; 1990 Nov; 34(11):2287-8. PubMed ID: 2073123
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis.
Mortensen JE; Rodgers GL
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():47-9. PubMed ID: 10824032
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Bordetella pertussis and Bordetella parapertussis to 24 antibiotics.
Hoppe JE; Haug A; Botzenhart K
Chemotherapy; 1987; 33(4):250-4. PubMed ID: 2886295
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Hoppe JE; Dalhoff A; Pfründer D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
[No Abstract] [Full Text] [Related]
6. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins.
Hoppe JE; Müller J
Antimicrob Agents Chemother; 1990 Jul; 34(7):1442-3. PubMed ID: 2386374
[TBL] [Abstract][Full Text] [Related]
7. Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis.
Hoppe JE; Tschirner T
Eur J Clin Microbiol Infect Dis; 1995 Sep; 14(9):775-9. PubMed ID: 8536725
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
Hoppe JE; Bryskier A
Antimicrob Agents Chemother; 1998 Apr; 42(4):965-6. PubMed ID: 9559823
[TBL] [Abstract][Full Text] [Related]
9. [Susceptibility to macrolide antibiotics of Bordetella pertussis and Bordetella parapertussis strains isolated from whooping cough patients in 1968 and in 1997-99].
Chodorowska M; Kuklińska D; Tyski S
Med Dosw Mikrobiol; 2001; 53(1):39-43. PubMed ID: 11757403
[TBL] [Abstract][Full Text] [Related]
10. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
Appleman ME; Hadfield TL; Gaines JK; Winn RE
Diagn Microbiol Infect Dis; 1987 Oct; 8(2):131-3. PubMed ID: 2892608
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
Hu BS; Fung CP; Liu PY; Lau YJ; Shi ZY; Lin YH
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct; 60(4):191-4. PubMed ID: 9439047
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Kitzis MD; Goldstein FW; Miegi M; Acar JF
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
16. Two Distinct Episodes Of Whooping Cough Caused By Consecutive Bordetella Pertussis And Bordetella Parapertussis Infections In A Fully Immunized Healthy Boy.
Heininger U; Schlassa D
Pediatr Infect Dis J; 2016 Nov; 35(11):1275-1276. PubMed ID: 27391699
[TBL] [Abstract][Full Text] [Related]
17. A recombinant iron transport protein from Bordetella pertussis confers protection against Bordetella parapertussis.
Alvarez Hayes J; Oviedo JM; Valdez H; Laborde JM; Maschi F; Ayala M; Shah R; Fernandez Lahore M; Rodriguez ME
Microbiol Immunol; 2017 Oct; 61(10):407-415. PubMed ID: 28857261
[TBL] [Abstract][Full Text] [Related]
18. Whooping cough in Pakistan: Bordetella pertussis vs Bordetella parapertussis in 2005-2009.
Bokhari H; Said F; Syed MA; Mughal A; Kazi YF; Heuvelman K; Mooi FR
Scand J Infect Dis; 2011 Oct; 43(10):818-20. PubMed ID: 21563881
[TBL] [Abstract][Full Text] [Related]
19. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection.
Wirsing von König CH; Finger H
Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):455-8. PubMed ID: 7957264
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Bordetella pertussis to cephalosporin derivatives and imipenem.
Bannatyne RM; Cheung R
Antimicrob Agents Chemother; 1984 Oct; 26(4):604-5. PubMed ID: 6097171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
